Medical Pharmacology: Chapter 11: Antilipidemic Drugs -- Module 1: Lipids, Lipoproteins, and Cardiovascular Risk

Chapter 11: Antilipidemic Drugs — Module 1: Lipids, Lipoproteins, and Cardiovascular Risk — The Pharmacological Foundation
Tier: T3 — Clinical Vignette (11 questions)

1. A 62-year-old man with type 2 diabetes and established ASCVD has been on atorvastatin 80 mg daily for 14 months. He presents to clinic reporting bilateral thigh and calf aching that began approximately six weeks ago and has been gradually worsening. He denies fever, rash, dark urine, or recent illness. He takes no other medications known to interact with statins. On examination, his thighs are mildly tender to palpation bilaterally. His creatine kinase (CK) is 620 U/L (reference range: 22–198 U/L; approximately 3× upper limit of normal [ULN]). His renal function is normal. Which of the following represents the most appropriate next step in management of this patient's statin-associated muscle symptom?

A) Discontinue atorvastatin immediately and permanently, as any CK elevation above the ULN in a patient with bilateral muscle symptoms constitutes a contraindication to all statin therapy regardless of magnitude, and the patient should be transitioned to a non-statin lipid-lowering regimen consisting of ezetimibe plus a PCSK9 inhibitor.
B) Continue atorvastatin 80 mg without change, as a CK elevation of 3× ULN in the absence of dark urine is below the threshold of clinical concern; obtain a repeat CK in 90 days and reassure the patient that mild asymptomatic CK elevations are an expected pharmacodynamic effect of high-intensity statin therapy rather than a sign of muscle injury.
C) Hold atorvastatin, recheck CK in two to four weeks after symptoms and CK have had time to resolve, then reassess for rechallenge with the same or an alternative lower-intensity statin — because guideline thresholds for permanent discontinuation require CK elevation greater than 10× ULN or evidence of myoglobinuria/renal impairment, neither of which is present here, and this patient retains statin eligibility.
D) Switch immediately from atorvastatin to rosuvastatin 40 mg without a drug holiday, as rosuvastatin is a hydrophilic statin with lower skeletal muscle penetration and can be substituted in real time without a washout period to resolve statin-associated myalgia while maintaining equivalent LDL-C reduction.
E) Obtain a skeletal muscle biopsy before making any therapeutic change, as bilateral statin-associated myalgia with CK elevation requires histological confirmation of type II fiber atrophy before a clinical diagnosis of statin-associated muscle syndrome can be made and documented in the medical record.

ANSWER: C

Rationale:

The correct answer is C. Statin-associated muscle symptoms (SAMS) range from benign myalgia (symptoms without significant CK elevation) through myositis (symptoms with CK elevation) to rhabdomyolysis (CK >10× ULN with myoglobinuria and risk of acute kidney injury). This patient has symptomatic myositis with a CK of approximately 3× ULN — a clinically significant but non-emergency presentation. The ACC/AHA and NLA guidelines recommend holding statin therapy when symptomatic CK elevation is present, allowing both symptoms and CK to normalize (typically over two to four weeks), and then reassessing for rechallenge. The threshold for permanent discontinuation of all statins is CK elevation exceeding 10× ULN, myoglobinuria, or renal impairment consistent with rhabdomyolysis — none of which are present here. Most patients with SAMS at this level can be successfully rechallenged with the same statin at a lower dose, a different statin (particularly a hydrophilic agent such as rosuvastatin or pravastatin), or an alternate-day dosing strategy. Permanent abandonment of all statin therapy after a single episode of 3× ULN CK elevation would deprive a high-risk ASCVD patient of his most evidence-based secondary prevention agent prematurely. Option A: Option B: Option D: Option E:

Option A: Option A is incorrect; a CK elevation of 3× ULN with symptoms does not constitute a permanent contraindication to all statin therapy — guideline thresholds for permanent discontinuation are substantially higher, and rechallenge after symptom and CK resolution is both appropriate and guideline-endorsed for this presentation.
Option B: Option B is incorrect; a symptomatic patient with bilateral muscle tenderness and CK at 3× ULN should not have therapy continued unchanged — this presentation warrants a drug holiday and reassessment, not reassurance and a 90-day follow-up interval.
Option D: Option D is incorrect in recommending an in-place switch without a drug holiday; when a patient has active symptomatic myositis with CK elevation, the statin should be held entirely until symptoms and CK resolve before any rechallenge or switch — substituting an alternative statin without a washout does not allow assessment of whether symptoms are truly statin-related and risks continued muscle injury.
Option E: Option E is incorrect; skeletal muscle biopsy is not required for the diagnosis or management of statin-associated myalgia or myositis at this severity level — it is occasionally considered in cases of severe or recurrent unexplained myopathy but is not a prerequisite for clinical decision-making in a straightforward SAMS presentation.

2. A 71-year-old man with a history of myocardial infarction two years prior is on simvastatin 40 mg nightly, aspirin, metoprolol, and lisinopril. He presents to urgent care with a five-day history of productive cough, fever, and right lower lobe infiltrate consistent with community-acquired pneumonia. His creatinine is 1.1 mg/dL. His physician prescribes a standard five-day course of clarithromycin 500 mg twice daily. Three days later he calls reporting severe bilateral leg pain, muscle weakness, and dark-colored urine. His CK returns at greater than 40,000 U/L and his creatinine has risen to 2.8 mg/dL. Which of the following best explains the mechanism of this complication?

A) Clarithromycin is a potent inhibitor of CYP3A4, the cytochrome P450 isoform responsible for the majority of simvastatin's hepatic first-pass and systemic metabolism; co-administration dramatically elevates simvastatin plasma concentrations by blocking its primary elimination pathway, producing systemic statin levels sufficient to cause rhabdomyolysis with acute kidney injury.
B) Clarithromycin inhibits the hepatic organic anion transporting polypeptide 1B1 (OATP1B1) transporter, which is responsible for delivering simvastatin acid from portal blood into hepatocytes for biliary elimination; transporter inhibition traps simvastatin acid in the systemic circulation at concentrations sufficient to cause rhabdomyolysis.
C) Clarithromycin activates skeletal muscle mitochondrial uncoupling by inhibiting complex I of the electron transport chain, and this effect is synergistic with simvastatin's independent reduction of coenzyme Q10 (ubiquinol) in skeletal muscle, producing combined mitochondrial dysfunction severe enough to cause rhabdomyolysis at otherwise tolerated simvastatin doses.
D) Clarithromycin displaces simvastatin from plasma albumin binding sites, increasing the free fraction of the drug available for skeletal muscle uptake; because simvastatin is highly protein-bound at therapeutic doses, even a small displacement produces a disproportionate increase in free simvastatin concentration at the muscle membrane.
E) Clarithromycin induces the hepatic CYP3A4 isoform after several days of administration, paradoxically increasing conversion of simvastatin to its active acid metabolite at a rate that exceeds hepatic first-pass clearance capacity, resulting in spillover of active statin acid into the systemic circulation at toxic concentrations.

ANSWER: A

Rationale:

The correct answer is A. Simvastatin is an HMG-CoA reductase inhibitor with high first-pass hepatic extraction; its systemic bioavailability is normally limited because it is extensively metabolized by CYP3A4 in the intestinal wall and liver before reaching systemic circulation. Clarithromycin is a potent mechanism-based inhibitor of CYP3A4 — it forms a stable inhibitory complex with the enzyme that lasts beyond the duration of drug administration. When clarithromycin is co-administered with simvastatin, CYP3A4 inhibition dramatically reduces simvastatin's first-pass and systemic elimination, causing plasma simvastatin concentrations to rise to levels many times higher than achieved with simvastatin alone. These elevated systemic levels produce skeletal muscle toxicity: HMG-CoA reductase inhibition in skeletal muscle impairs mevalonate pathway-dependent processes (including coenzyme Q10 synthesis and protein prenylation) at concentrations that would not be reached at normal simvastatin exposure. This patient has developed frank rhabdomyolysis — CK >40,000 U/L with myoglobinuria causing acute kidney injury. This interaction is specifically contraindicated in FDA prescribing information for simvastatin. The hydrophilic statins (rosuvastatin, pravastatin) and fluvastatin (CYP2C9 substrate) carry substantially lower risk with CYP3A4 inhibitors. Option B: Option C: Option D: Option E:

Option B: Option B is incorrect; while OATP1B1 is a clinically important hepatic uptake transporter relevant to statin pharmacokinetics — and its inhibition can increase statin systemic exposure — the primary mechanism of the clarithromycin-simvastatin interaction is CYP3A4 inhibition, not OATP1B1 inhibition; clarithromycin is not a clinically significant OATP1B1 inhibitor.
Option C: Option C is incorrect; clarithromycin does not cause rhabdomyolysis by inhibiting mitochondrial complex I, and while statin-associated coenzyme Q10 depletion has been proposed as a contributing mechanism to SAMS, it is not the basis of the clarithromycin-simvastatin interaction — which is entirely pharmacokinetic.
Option D: Option D is incorrect; protein displacement drug interactions are rarely clinically significant because the displaced drug is also available for increased clearance — simvastatin's elevated plasma levels in this interaction are due to impaired metabolic elimination, not protein displacement.
Option E: Option E is incorrect; clarithromycin is an inhibitor of CYP3A4, not an inducer — it reduces, not increases, CYP3A4-mediated metabolism; induction of CYP3A4 would in fact lower simvastatin exposure rather than raise it.

3. A 29-year-old woman with heterozygous familial hypercholesterolemia (HeFH) confirmed by genetic testing presents for preconception counseling. She has been on rosuvastatin 20 mg daily for three years with excellent LDL-C control — her LDL-C is currently 118 mg/dL, down from 248 mg/dL at diagnosis. She has no cardiovascular events and no end-organ damage. She and her partner are planning to attempt conception within the next two to three months. Her primary care physician is reviewing her medication list. Which of the following best describes the appropriate management of her statin therapy in the context of pregnancy planning?

A) Rosuvastatin should be continued throughout pregnancy at the current dose because the cardiovascular risk of uncontrolled LDL-C in a patient with HeFH is greater than the theoretical teratogenic risk, and current FDA guidance has moved away from categorical pregnancy contraindications for all statins following reassessment of the risk-benefit profile in high-risk lipid disorders.
B) Rosuvastatin should be reduced to the lowest available dose (5 mg daily) and continued during the first trimester only, then discontinued at the start of the second trimester when organogenesis is complete and the risk of structural teratogenicity from cholesterol pathway inhibition is no longer present.
C) Rosuvastatin should be switched immediately to a bile acid sequestrant such as colesevelam, which is the only lipid-lowering agent approved for use throughout all three trimesters of pregnancy; colesevelam is preferred because it does not cross the placenta and has not been associated with fetal adverse effects in registry data.
D) Rosuvastatin should be discontinued at conception and replaced with high-dose omega-3 fatty acid supplementation as a bridge therapy during pregnancy, as omega-3 fatty acids are the only pharmacological intervention with a category B safety designation for use in pregnant women with dyslipidemias including familial hypercholesterolemia.
E) Rosuvastatin should be discontinued before conception — ideally one to two months prior to attempting pregnancy — and not restarted until breastfeeding is complete; statins inhibit the mevalonate pathway, which is critical for fetal cholesterol synthesis, membrane biosynthesis, and steroidogenesis during organogenesis, and all statins carry a contraindication in pregnancy with limited exceptions; bile acid sequestrants or watchful waiting are the standard approach during pregnancy in HeFH.

ANSWER: E

Rationale:

The correct answer is E. Statins are contraindicated in pregnancy. The mechanistic basis is well-established: the mevalonate pathway, which statins inhibit, is essential for fetal cholesterol synthesis during organogenesis. Fetal cholesterol is required for cell membrane biosynthesis, myelination, bile acid precursor synthesis, and steroidogenesis — all of which are critical during embryonic and fetal development. Although the absolute teratogenic risk from inadvertent first-trimester statin exposure appears lower than initially estimated from early case reports, the FDA label for all statins retains a contraindication in pregnancy, and no statin has been demonstrated safe for use in human pregnancy in adequately powered prospective trials. The standard guidance is to discontinue statins before conception — one to two months prior to attempting pregnancy is the conventional recommendation — and not restart until after delivery and completion of breastfeeding, as statins also pass into breast milk. During pregnancy, women with HeFH are typically managed with diet modification and bile acid sequestrants if pharmacological therapy is deemed necessary, though many clinicians opt for watchful waiting given the short duration of the pregnancy period in the context of lifetime ASCVD risk. The LDL-C rise during pregnancy (physiological) is acknowledged and accepted for the duration of gestation in the majority of FH patients without established cardiovascular disease. Option A: Option B: Option C: Option D:

Option A: Option A is incorrect; FDA labeling continues to contraindicate statin use in pregnancy across all agents, including rosuvastatin; while risk re-evaluation has led to removal of the prior X category designation in the new pregnancy and lactation labeling framework, this does not constitute approval for use — the contraindication remains, and continuation of statin therapy through pregnancy is not guideline-endorsed.
Option B: Option B is incorrect; there is no guideline-endorsed strategy of using a reduced statin dose during the first trimester only — statin discontinuation before conception is the standard recommendation, and any continued statin exposure during organogenesis carries teratogenic risk regardless of dose.
Option C: Option C is incorrect; colesevelam is sometimes used in pregnancy for its favorable safety profile (minimal systemic absorption), but it is not FDA-approved for pregnancy and is not described as the "only approved agent for all three trimesters" — the framing of this option is inaccurate and overstates the evidence base.
Option D: Option D is incorrect; omega-3 fatty acids are used for hypertriglyceridemia, not for LDL-C lowering in familial hypercholesterolemia, and high-dose omega-3 supplementation is not the standard bridge therapy for statin-intolerant or statin-contraindicated patients with FH during pregnancy.

4. A 44-year-old man with poorly controlled type 2 diabetes (HbA1c 10.2%) and a two-drink-per-day alcohol intake presents to the emergency department with acute-onset epigastric pain radiating to the back, nausea, and vomiting. His fasting lipid panel drawn in the ED reveals: triglycerides 1,840 mg/dL, LDL-C unable to be calculated (Friedewald equation invalid above 400 mg/dL), HDL-C 22 mg/dL, total cholesterol 310 mg/dL. Lipase is elevated at 4× ULN. Imaging confirms acute pancreatitis without necrosis. After appropriate supportive management, he is medically stable and ready for discharge planning. His only current medication is metformin. Which of the following represents the most appropriate pharmacological strategy to prevent recurrent hypertriglyceridemia-induced pancreatitis in this patient?

A) Initiate high-intensity statin therapy with rosuvastatin 40 mg daily as the priority intervention, because although statins have a modest triglyceride-lowering effect of only 10 to 20%, they also reduce VLDL production through SREBP-2 pathway modulation, and the ACC/AHA 2018 guideline designates high-intensity statin as the first-line pharmacological agent for all patients with triglyceride-mediated pancreatitis regardless of LDL-C level.
B) Initiate a fibrate (fenofibrate or gemfibrozil) as the primary triglyceride-lowering agent, because fibrates activate PPAR-alpha, upregulating lipoprotein lipase expression and activity while suppressing apolipoprotein C-III (apoC-III) synthesis, collectively increasing VLDL triglyceride catabolism and reducing VLDL production — effects that routinely lower triglycerides by 40 to 60% and are the cornerstone of pharmacological management for hypertriglyceridemia above 500 mg/dL.
C) Initiate high-dose omega-3 fatty acid therapy (icosapentaenoic acid [EPA] plus docosahexaenoic acid [DHA], 4 g daily) as monotherapy, because prescription omega-3 formulations are FDA-approved for severe hypertriglyceridemia above 500 mg/dL and achieve triglyceride reductions of 40 to 50% through reduction of hepatic VLDL synthesis and enhanced triglyceride clearance, making them equivalent to fibrates as a first-line agent in this setting.
D) Initiate niacin 1,500 mg daily as the preferred agent because niacin produces the greatest combined effect on the atherogenic lipid triad — reducing triglycerides by 30 to 40%, raising HDL-C by 20 to 35%, and lowering LDL-C by 15 to 25% — and is the only lipid-lowering agent that simultaneously addresses all three components of this patient's dyslipidemia in a single drug.
E) Defer pharmacological therapy pending glycemic optimization alone, because the patient's severe hypertriglyceridemia is entirely secondary to his poorly controlled diabetes and alcohol use; once HbA1c is normalized and alcohol is discontinued, triglycerides will fall spontaneously to non-dangerous levels without pharmacological intervention, and premature drug therapy masks the primary etiology.

ANSWER: B

Rationale:

The correct answer is B. When fasting triglycerides exceed 500 mg/dL — and especially at levels above 1,000 mg/dL — the risk of acute pancreatitis from chylomicronemia becomes clinically significant, and this patient has already experienced one episode. Fibrates are the established first-line pharmacological agents for severe hypertriglyceridemia. Fenofibrate and gemfibrozil activate peroxisome proliferator-activated receptor alpha (PPAR-alpha) in the liver, which upregulates lipoprotein lipase (LPL) transcription and activity, increasing catabolism of VLDL and chylomicron triglycerides. PPAR-alpha activation simultaneously suppresses apoC-III synthesis — apoC-III is a potent endogenous inhibitor of LPL — so fibrate therapy removes the brake on triglyceride hydrolysis while accelerating it. Additionally, PPAR-alpha reduces hepatic VLDL-TG synthesis. These combined mechanisms produce triglyceride reductions of 40 to 60%, making fibrates the most reliably effective pharmacological class for acute triglyceride reduction in this setting. This patient should also be counseled on alcohol cessation, dietary fat restriction (less than 15% of calories from fat), and aggressive glycemic control — all of which are essential co-interventions — but fibrate therapy is the pharmacological cornerstone of pancreatitis prevention in this context. Option A: Option C: Option D: Option E:

Option A: Option A is incorrect; while statins have a modest triglyceride-lowering effect of approximately 10 to 20%, they are not first-line for severe hypertriglyceridemia above 500 mg/dL and are not designated by ACC/AHA guidelines as the primary agent for hypertriglyceridemia-induced pancreatitis; LDL-C cannot be calculated at this triglyceride level, and the primary clinical urgency is triglyceride reduction, not LDL-C lowering.
Option C: Option C is incorrect; prescription omega-3 fatty acids (EPA/DHA combinations such as Lovaza) are FDA-approved for triglycerides above 500 mg/dL and do reduce triglycerides meaningfully, but they are generally considered adjunctive or second-line to fibrates in severe hypertriglyceridemia and do not have the same breadth of evidence as fibrates for pancreatitis prevention at this severity level; pure EPA (icosapentaenoic acid, as in vascepa) is specifically approved for cardiovascular risk reduction in a different clinical context.
Option D: Option D is incorrect; niacin has largely fallen out of first-line use for severe hypertriglyceridemia due to its tolerability profile, its lack of demonstrated cardiovascular outcomes benefit in contemporary trials (AIM-HIGH, HPS2-THRIVE), and the superior triglyceride-lowering efficacy of fibrates in this indication; niacin is also relatively contraindicated in poorly controlled diabetes due to its insulin-antagonizing effect on adipose tissue.
Option E: Option E is incorrect; while glycemic optimization and alcohol cessation are essential, deferring all pharmacological therapy in a patient who has just experienced hypertriglyceridemia-induced pancreatitis with TGs of 1,840 mg/dL is inappropriate — the recurrence risk is substantial, and fibrate therapy should be initiated alongside lifestyle and glycemic interventions, not withheld pending their effect.

5. A 58-year-old man with type 2 diabetes and mixed dyslipidemia presents for a lipid management follow-up. His current fasting lipid panel on atorvastatin 40 mg daily shows: LDL-C 102 mg/dL, HDL-C 38 mg/dL, triglycerides 310 mg/dL, total cholesterol 202 mg/dL. His 10-year ASCVD risk is 18% (high risk), and his target LDL-C is below 70 mg/dL. His physician wants to add a second agent to achieve further LDL-C reduction. She is considering adding colesevelam, noting that it is sometimes used in type 2 diabetes because it has a modest glucose-lowering effect in addition to LDL-C reduction. Which of the following statements best identifies the most clinically important limitation of adding colesevelam in this specific patient?

A) Colesevelam should not be combined with statins in patients with type 2 diabetes because bile acid sequestrants inhibit CYP7A1 (cholesterol 7-alpha-hydroxylase) in the liver, reducing the rate-limiting step of bile acid synthesis and paradoxically increasing hepatic cholesterol content — an effect that offsets statin-mediated LDLR upregulation and blunts the expected additive LDL-C lowering.
B) Colesevelam is contraindicated with atorvastatin specifically because it binds and sequesters atorvastatin in the intestinal lumen, reducing atorvastatin bioavailability by more than 70% when the two agents are taken simultaneously; the interaction cannot be mitigated by dose separation and renders the combination pharmacologically ineffective.
C) Colesevelam produces a significant reduction in fat-soluble vitamin absorption (vitamins A, D, E, and K), and in a patient on atorvastatin — which also depletes coenzyme Q10 — the combined nutrient-depletion burden creates a clinically significant risk of osteomalacia, coagulopathy, and mitochondrial dysfunction that outweighs the modest LDL-C reduction achievable with this combination.
D) Colesevelam, like all bile acid sequestrants, can raise triglycerides by 5 to 20% or more in patients with baseline hypertriglyceridemia; in this patient whose triglycerides are already elevated at 310 mg/dL, adding colesevelam risks a further triglyceride rise that could approach the threshold for pancreatitis risk, making ezetimibe a preferable second-line agent for additional LDL-C lowering in this lipid phenotype.
E) Colesevelam reduces LDL-C by only 12 to 16% as monotherapy and has no additive LDL-C-lowering effect when combined with a statin, because both agents work through the same final mechanism of LDLR upregulation via hepatic cholesterol depletion; the combination produces no greater LDLR surface density than the statin alone at equivalent doses.

ANSWER: D

Rationale:

The correct answer is D. Bile acid sequestrants — including colesevelam, cholestyramine, and colestipol — interrupt the enterohepatic circulation of bile acids, reducing their reabsorption from the terminal ileum. The liver compensates by upregulating CYP7A1 (cholesterol 7-alpha-hydroxylase) to convert more hepatic cholesterol into bile acids, depleting intrahepatic cholesterol and activating SREBP-2 to upregulate LDLR — the desired mechanism for LDL-C lowering. However, bile acid sequestrants have a well-established and clinically important adverse effect on triglycerides: by reducing bile acid return to the liver, they stimulate hepatic VLDL-TG production as part of the compensatory lipogenic response, raising triglycerides by 5 to 20% or more. In patients with baseline triglycerides already below 200 mg/dL, this rise is generally manageable. However, in patients with pre-existing hypertriglyceridemia — as in this patient with triglycerides of 310 mg/dL — adding a bile acid sequestrant risks a further clinically significant triglyceride increase that could approach or exceed the 500 mg/dL threshold associated with pancreatitis risk. For this reason, bile acid sequestrants are generally considered relatively contraindicated when baseline triglycerides exceed 300 to 400 mg/dL. Ezetimibe (NPC1L1 inhibitor) is a preferable second-line agent in this patient because it lowers LDL-C by an additional 18 to 20% when added to a statin without adversely affecting triglycerides. Option A: Option B: Option C: Option E:

Option A: Option A is incorrect; colesevelam does not inhibit CYP7A1 — it actually stimulates CYP7A1 upregulation by reducing bile acid return; the premise of the option reverses the actual pharmacodynamic mechanism.
Option B: Option B is incorrect; while bile acid sequestrants can bind some medications in the gut lumen, the interaction with atorvastatin is not as severe as described — the standard guidance is to take atorvastatin at least one hour before or four hours after the sequestrant, which largely mitigates absorption interference; this is not a contraindication to the combination.
Option C: Option C is incorrect; while bile acid sequestrants can reduce fat-soluble vitamin absorption with long-term use, this is not the primary clinical limitation of colesevelam in this patient — it does not create the "combined nutrient-depletion burden" described, and coenzyme Q10 depletion by statins is a proposed but unproven mechanism for SAMS, not a validated nutrient interaction requiring clinical management in all statin users.
Option E: Option E is incorrect; colesevelam and statins have additive LDL-C-lowering effects despite both ultimately upregulating LDLR — they work through complementary upstream mechanisms (reduced synthesis versus reduced absorption), and the combination is guideline-endorsed when triglyceride levels are not elevated.

6. A 47-year-old woman with heterozygous familial hypercholesterolemia (HeFH) confirmed by the Dutch Lipid Clinic Network criteria presents for lipid management follow-up. She has no personal history of cardiovascular events but has a family history of premature coronary artery disease in her father (MI at age 52) and her brother (MI at age 56). She has been on rosuvastatin 40 mg daily (high-intensity) for six months with good adherence confirmed by pharmacy refill records. Her repeat fasting lipid panel shows: LDL-C 148 mg/dL, down from a baseline of 226 mg/dL — a 34% reduction. Her physician discusses her treatment target of LDL-C below 100 mg/dL (and ideally below 70 mg/dL given her family history burden). Which of the following represents the most appropriate next pharmacological step per current ACC/AHA guidelines?

A) Add ezetimibe 10 mg daily to her current rosuvastatin, as ACC/AHA 2018 guidelines endorse adding ezetimibe as the preferred next-line agent when high-intensity statin therapy does not achieve the LDL-C goal in FH patients — ezetimibe lowers LDL-C by an additional 18 to 20% through NPC1L1 inhibition in the gut, complementing the statin's SREBP-2-mediated LDLR upregulation by a non-redundant mechanism.
B) Switch rosuvastatin to atorvastatin 80 mg daily, as atorvastatin 80 mg is the highest-potency statin available and achieves greater LDL-C reduction than rosuvastatin 40 mg through more complete HMG-CoA reductase inhibition; switching to the most potent available statin should always be the next step before adding a second drug class in familial hypercholesterolemia.
C) Add a PCSK9 inhibitor (evolocumab or alirocumab) immediately, as FH patients who do not achieve LDL-C goal on high-intensity statin therapy qualify directly for PCSK9 inhibitor therapy without an intermediate ezetimibe step, because PCSK9 inhibitors produce superior LDL-C lowering (50 to 60% reduction) and their cardiovascular outcomes benefit has been demonstrated in high-risk FH patients in the FOURIER and ODYSSEY OUTCOMES trials.
D) Add colesevelam to her current rosuvastatin, as bile acid sequestrants are the preferred second-line agents in FH patients because they address the enterohepatic cholesterol cycle that is not targeted by statin therapy, and colesevelam specifically has demonstrated LDL-C lowering of 30 to 35% when added to high-intensity statin therapy in FH patients with baseline LDL-C above 130 mg/dL.
E) Refer for LDL apheresis, as this patient's LDL-C remains above 100 mg/dL despite six months of high-intensity statin monotherapy, which meets the ACC/AHA threshold criterion for LDL apheresis referral in HeFH patients who fail to achieve guideline-recommended LDL-C goals on pharmacological therapy.

ANSWER: A

Rationale:

The correct answer is A. The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol provides a stepwise approach to LDL-C lowering in patients with familial hypercholesterolemia. When high-intensity statin therapy does not achieve the LDL-C goal — which in HeFH with high family history burden is typically below 100 mg/dL or below 70 mg/dL — the guideline-endorsed next step is the addition of ezetimibe before escalating to PCSK9 inhibitors. Ezetimibe inhibits NPC1L1, reducing intestinal cholesterol absorption and decreasing hepatic cholesterol delivery, which triggers additional SREBP-2-mediated LDLR upregulation. Added to a high-intensity statin, ezetimibe typically lowers LDL-C by an additional 18 to 20%, and the combination is expected to bring this patient's LDL-C from 148 mg/dL down to approximately 118 to 122 mg/dL — closer to but potentially still short of the below-70 goal. The sequencing of ezetimibe before PCSK9 inhibitors is driven by cost-effectiveness: ezetimibe is inexpensive and generically available, whereas PCSK9 inhibitors carry substantial cost. This patient is not yet a candidate for LDL apheresis because she has not failed combination pharmacological therapy. Option B: Option C: Option D: Option E:

Option B: Option B is incorrect; rosuvastatin 40 mg and atorvastatin 80 mg are both classified as high-intensity statins by the ACC/AHA, achieving comparable LDL-C reductions of approximately 50% or more from baseline — switching between high-intensity statins of similar potency is not a guideline-recommended strategy for intensifying therapy and will not meaningfully change her LDL-C further.
Option C: Option C is incorrect; while PCSK9 inhibitors are ultimately an appropriate escalation in HeFH patients who remain above goal, the ACC/AHA guideline endorses a stepwise approach with ezetimibe as the preferred intermediate step before PCSK9 inhibitors based on cost-effectiveness — PCSK9 inhibitors are recommended when statin plus ezetimibe combination therapy fails to achieve goal, not when statin monotherapy alone is insufficient.
Option D: Option D is incorrect; bile acid sequestrants are not the preferred second-line agents in FH — ezetimibe is. Additionally, the claim that colesevelam reduces LDL-C by 30 to 35% as add-on therapy in FH is not accurate; colesevelam typically reduces LDL-C by 12 to 16% as monotherapy, with modest additive effect on top of a statin, and is further limited in patients with any degree of hypertriglyceridemia.
Option E: Option E is incorrect; LDL apheresis is reserved for patients who have failed maximally tolerated pharmacological therapy — including statin, ezetimibe, and PCSK9 inhibitor combinations — not for patients who are still on statin monotherapy after six months; this patient has only had one drug tried, and combination pharmacological options have not been exhausted.

7. A 66-year-old man with stage 3b chronic kidney disease (CKD; eGFR 32 mL/min/1.73 m²), type 2 diabetes, and hypertension presents for cardiovascular risk management. His LDL-C is 138 mg/dL. He has no prior cardiovascular events. His nephrologist and cardiologist agree that a high-intensity statin is indicated given his risk profile. A medical student rotating on the service asks why simvastatin 80 mg — which the patient had previously been on before his CKD progressed — is no longer the preferred agent. Which of the following best explains the pharmacokinetic rationale for preferring rosuvastatin over simvastatin in a patient with advanced CKD?

A) Rosuvastatin is preferred because it undergoes extensive renal clearance of its active acid form, and in patients with reduced GFR, renal accumulation of rosuvastatin acid achieves greater hepatic LDLR upregulation than is possible with simvastatin; the higher intrahepatic concentration produces superior LDL-C reduction without proportionally increasing systemic statin exposure.
B) Simvastatin 80 mg is associated with a higher rate of myopathy than lower-intensity statins, and the FDA issued a safety communication restricting new initiation of simvastatin 80 mg in 2011; the avoidance of simvastatin in CKD is based entirely on this FDA restriction rather than any pharmacokinetic concern specific to renal impairment.
C) Rosuvastatin is preferred in CKD because it is minimally metabolized by CYP enzymes and is primarily eliminated by biliary/fecal routes rather than renal excretion of active drug; its pharmacokinetic profile is not significantly altered by reduced GFR, making dose adjustment unnecessary in stage 3 CKD and its systemic exposure profile more predictable — in contrast to simvastatin, which is a CYP3A4 substrate and whose active metabolite simvastatin acid has pharmacokinetic properties that increase myopathy risk when renal elimination is impaired.
D) Rosuvastatin is preferred because it is a prodrug that requires renal activation to simvastatin acid, and in patients with CKD the reduced renal clearance paradoxically increases the conversion of inactive prodrug to active acid form, producing greater hepatocellular HMG-CoA reductase inhibition with lower systemic drug exposure compared to simvastatin in the same patient.
E) Simvastatin is avoided in CKD primarily because it inhibits the renal organic anion transporter OAT3, which is responsible for tubular secretion of several metabolic waste products including urea precursors; competitive inhibition of OAT3 by simvastatin accelerates the rise in serum creatinine independently of any effect on GFR, creating a false impression of CKD progression that confounds monitoring.

ANSWER: C

Rationale:

The correct answer is C. The choice of statin in patients with chronic kidney disease is informed by pharmacokinetic considerations that affect both efficacy and safety. Rosuvastatin is a hydrophilic statin that is minimally metabolized by cytochrome P450 enzymes — it undergoes limited CYP2C9-mediated metabolism and is primarily eliminated via biliary/fecal routes as unchanged drug. Its pharmacokinetics are not substantially altered by reduced glomerular filtration rate (GFR) in stage 3 CKD, and dose adjustment is not required until very advanced CKD (stage 5 or dialysis). Simvastatin, by contrast, is a lipophilic lactone prodrug hydrolyzed to simvastatin acid — the active HMG-CoA reductase inhibitor. Simvastatin and its active acid are CYP3A4 substrates; simvastatin acid also undergoes some degree of renal elimination. In CKD, impaired renal clearance of simvastatin acid, combined with reduced plasma protein binding (due to hypoalbuminemia common in CKD), can increase free simvastatin acid exposure, raising myopathy risk. Additionally, the FDA issued a safety communication in 2011 restricting new prescriptions of simvastatin 80 mg due to high myopathy rates — though this restriction applies broadly, not only to CKD patients. The SHARP trial (Study of Heart and Renal Protection) specifically examined simvastatin 20 mg plus ezetimibe 10 mg in patients with CKD and demonstrated significant cardiovascular event reduction, supporting the statin class broadly in this population. Rosuvastatin's favorable pharmacokinetic profile in CKD — predictable exposure, biliary elimination, minimal CYP interaction — makes it the preferred high-intensity statin when CKD is present. Option A: Option B: Option D: Option E:

Option A: Option A is incorrect; rosuvastatin undergoes limited renal excretion of active drug — its primary elimination is biliary, not renal — and the rationale for its preference in CKD is the absence of pharmacokinetic disruption by reduced GFR, not enhanced renal accumulation producing greater LDLR upregulation.
Option B: Option B is incorrect in stating that avoidance of simvastatin in CKD is based entirely on the FDA 80 mg restriction — while that restriction is real, the pharmacokinetic case for avoiding high-dose simvastatin in CKD is an independent consideration based on impaired clearance of active drug and increased myopathy risk.
Option D: Option D is incorrect; rosuvastatin is not a prodrug requiring renal activation — it is administered as the active acid form and does not require conversion to a different active species; the premise of the option is pharmacologically inaccurate.
Option E: Option E is incorrect; simvastatin does not clinically inhibit the renal OAT3 transporter in a manner that falsely elevates creatinine — this is not an established mechanism of simvastatin action or a recognized drug-kidney interaction.

8. A 59-year-old man with established ASCVD (prior CABG at age 55) is on rosuvastatin 40 mg plus ezetimibe 10 mg. His most recent LDL-C is 92 mg/dL, above his target of below 70 mg/dL. His physician discusses adding a PCSK9-targeting agent and mentions two options: evolocumab (a monoclonal antibody against PCSK9) and inclisiran (a small interfering RNA [siRNA] agent targeting PCSK9 mRNA). The patient asks about the difference in how often he would need injections with each agent. The physician explains that the two drugs achieve similar LDL-C lowering by 50 to 60% but differ substantially in their mechanism of action and dosing schedule. Which of the following correctly distinguishes inclisiran from evolocumab with respect to both mechanism and dosing frequency?

A) Evolocumab is dosed every two weeks as a subcutaneous injection and works by forming a stable complex with PCSK9 protein in the extracellular space; inclisiran is dosed monthly and works by inhibiting the PCSK9 gene promoter via a CpG methylation mechanism in hepatocyte nuclei, producing durable epigenetic silencing of PCSK9 expression that persists for four to six weeks after each injection.
B) Evolocumab and alirocumab are monoclonal antibodies dosed every two to four weeks subcutaneously that directly bind and neutralize circulating PCSK9 protein, preventing PCSK9 from binding and targeting the LDL receptor for lysosomal degradation; inclisiran is a siRNA agent dosed twice yearly (at day 0, day 90, and then every six months thereafter) that is taken up by hepatocytes via GalNAc (N-acetylgalactosamine) conjugation and activates the RNA-induced silencing complex (RISC) to cleave PCSK9 mRNA before it is translated, eliminating PCSK9 synthesis at the source rather than neutralizing secreted protein.
C) Inclisiran is a monoclonal antibody dosed every four weeks that binds PCSK9 mRNA in the bloodstream before it exits the hepatocyte nucleus, preventing nuclear export and subsequent translation; evolocumab is a siRNA agent dosed every two weeks that enters hepatocytes and degrades mature PCSK9 protein within the endosome through cathepsin-mediated proteolysis activated by the RISC complex.
D) Evolocumab and inclisiran are both dosed every four weeks subcutaneously and achieve equivalent plasma PCSK9 suppression through complementary mechanisms — evolocumab neutralizes extracellular PCSK9 at the hepatocyte surface while inclisiran binds intracellular PCSK9 protein within the hepatocyte endoplasmic reticulum before secretion; together they are sometimes used in combination for maximum PCSK9 suppression in refractory familial hypercholesterolemia.
E) Inclisiran is dosed daily as an oral tablet that is absorbed in the small intestine and enters the portal circulation, where it is taken up by hepatocytes via OATP1B1 transporters; once intracellular, inclisiran binds the PCSK9 mRNA 3-prime untranslated region (UTR) as an antisense oligonucleotide, blocking ribosomal scanning and preventing PCSK9 protein synthesis without degrading the mRNA transcript.

ANSWER: B

Rationale:

The correct answer is B. Evolocumab (Repatha) and alirocumab (Praluent) are fully human monoclonal antibodies that bind PCSK9 — a serine protease secreted by hepatocytes — in the extracellular space, blocking PCSK9 from binding to the LDL receptor (LDLR) on the hepatocyte surface. By preventing PCSK9-mediated LDLR routing to lysosomes, these antibodies increase LDLR recycling and surface density, dramatically enhancing LDL-C clearance from plasma. They are administered subcutaneously every two weeks (evolocumab 140 mg; alirocumab 75 or 150 mg) or monthly at higher doses. Inclisiran (Leqvio) is a chemically synthesized small interfering RNA (siRNA) molecule conjugated to N-acetylgalactosamine (GalNAc), a sugar moiety that binds ASGR1 (asialoglycoprotein receptor 1) on hepatocytes with high affinity, enabling selective hepatocyte uptake. Once intracellular, inclisiran is loaded into the RNA-induced silencing complex (RISC), which uses the antisense strand of the siRNA as a guide to identify and cleave PCSK9 mRNA — preventing translation and eliminating de novo PCSK9 protein synthesis. This upstream mechanism produces durable suppression of PCSK9 with a prolonged pharmacodynamic effect, enabling the twice-yearly dosing schedule (initial dose at day 0, a second dose at day 90, then every six months thereafter). Both classes reduce LDL-C by approximately 50 to 60% on top of statin therapy and have robust efficacy data in high-risk patients. Option A: Option C: Option D: Option E:

Option A: Option A is incorrect in multiple respects: evolocumab is dosed every two to four weeks, not every two weeks exclusively; inclisiran is not dosed monthly; and inclisiran does not work via CpG methylation or epigenetic silencing — it uses RISC-mediated mRNA cleavage, which is a post-transcriptional rather than epigenetic mechanism.
Option C: Option C inverts the drug identities — inclisiran is the siRNA agent and evolocumab is the monoclonal antibody, not the reverse as described; inclisiran acts post-transcriptionally on mRNA in hepatocyte cytoplasm, not by preventing nuclear mRNA export.
Option D: Option D is incorrect; inclisiran is not dosed every four weeks — its distinctive clinical advantage is its twice-yearly maintenance dosing; neither drug is dosed every four weeks as standard, and the combination of both agents is not a guideline-endorsed clinical strategy.
Option E: Option E is incorrect; inclisiran is not an oral agent — it is a subcutaneous injection; inclisiran is not an antisense oligonucleotide (ASO) — ASOs and siRNAs are mechanistically distinct RNA-based modalities; and inclisiran is not taken up via OATP1B1 but via the GalNAc-ASGR1 hepatocyte targeting system.

9. A 67-year-old woman with established ASCVD (prior PCI for NSTEMI three years ago) reports intolerance to three separate statins — atorvastatin, rosuvastatin, and pravastatin — each of which caused reproducible proximal muscle pain with CK elevation that resolved upon discontinuation. She is currently on ezetimibe 10 mg daily. Her LDL-C is 118 mg/dL, above her secondary prevention target of below 70 mg/dL. Her cardiologist discusses adding bempedoic acid 180 mg daily as an additional LDL-C-lowering option. A resident rotating through the clinic asks how bempedoic acid differs mechanistically from a statin, given that both drugs reduce LDL-C by inhibiting cholesterol synthesis. Which of the following best describes the mechanism of bempedoic acid and explains why it is less likely to cause skeletal muscle toxicity than statins?

A) Bempedoic acid inhibits HMG-CoA reductase directly in hepatocytes by a mechanism distinct from statins — binding a different allosteric site on the enzyme rather than the active site — producing equivalent hepatic cholesterol synthesis inhibition with a smaller effect on mevalonate pathway intermediates (isoprenoids, coenzyme Q10) responsible for statin-associated myopathy.
B) Bempedoic acid is a prodrug that is activated by hepatic acyl-CoA synthetase to bempedoic acid-CoA, which then inhibits ACLY (ATP-citrate lyase) — an enzyme upstream of HMG-CoA reductase in the cholesterol synthesis pathway; because activation to the active CoA thioester requires an enzyme (ACSL1) that is expressed in the liver but not in skeletal muscle, bempedoic acid selectively inhibits hepatic cholesterol synthesis without producing meaningful drug concentrations or active drug in skeletal muscle tissue, explaining its significantly lower skeletal muscle toxicity compared to statins.
C) Bempedoic acid inhibits squalene synthase (farnesyl diphosphate farnesyltransferase) — the enzyme that condenses two farnesyl pyrophosphate molecules into squalene — which is the first committed step of cholesterol synthesis downstream of the mevalonate branch point; because squalene synthase inhibition occurs after the branch point for isoprenoid and coenzyme Q10 synthesis, bempedoic acid preserves mevalonate pathway intermediates in skeletal muscle and avoids the CoQ10 depletion proposed as a mechanism for statin myopathy.
D) Bempedoic acid acts as a selective liver X receptor (LXR) antagonist in hepatocytes, suppressing LXR-mediated induction of FASN (fatty acid synthase) and ACSS2 (acyl-CoA short chain synthetase 2), which are rate-limiting enzymes in the de novo lipogenesis pathway that provides acetyl-CoA substrate for cholesterol synthesis; because LXR is minimally expressed in skeletal muscle, bempedoic acid's hepatic selectivity is achieved through receptor expression rather than tissue-specific drug activation.
E) Bempedoic acid is a prodrug activated in the liver to bempedoic acid-CoA, which inhibits ATP-citrate lyase (ACLY) — an enzyme that cleaves cytosolic citrate into acetyl-CoA and oxaloacetate, providing the acetyl-CoA substrate for cholesterol synthesis upstream of HMG-CoA reductase; because the activating enzyme (very-long-chain acyl-CoA synthetase 1, ACSVL1/SLC27A2) is expressed in hepatocytes but not in skeletal muscle, the drug achieves liver-selective ACLY inhibition without generating active drug in muscle, producing hepatic cholesterol synthesis inhibition with a substantially lower risk of skeletal muscle toxicity.

ANSWER: E

Rationale:

The correct answer is E. Bempedoic acid (Nexletol) is an oral prodrug that requires activation to its CoA thioester form — bempedoic acid-CoA — by the enzyme very-long-chain acyl-CoA synthetase 1 (ACSVL1, also known as SLC27A2), which is expressed in hepatocytes but is absent or minimally expressed in skeletal muscle. Once activated in the liver, bempedoic acid-CoA inhibits ATP-citrate lyase (ACLY), the cytosolic enzyme that cleaves citrate (exported from the mitochondrial TCA cycle) into acetyl-CoA and oxaloacetate. This cytosolic acetyl-CoA is the foundational carbon donor for hepatic de novo cholesterol synthesis — the same pathway that statins interrupt at the HMG-CoA reductase step. By inhibiting ACLY upstream of HMG-CoA reductase, bempedoic acid reduces the acetyl-CoA substrate available for cholesterol synthesis, ultimately triggering SREBP-2-mediated LDLR upregulation and LDL-C lowering of approximately 18 to 28%. The critical tissue-selectivity advantage over statins is mechanistically rooted in the prodrug activation step: statins are active drugs that enter skeletal muscle cells and inhibit HMG-CoA reductase there, depleting mevalonate pathway intermediates in muscle. Bempedoic acid requires ACSVL1 for activation, and because skeletal muscle lacks this enzyme, the drug remains in its inactive prodrug form in muscle tissue — it cannot generate active ACLY inhibitor in muscle, and skeletal muscle is spared. This is confirmed in clinical trials: the CLEAR Serenity trial demonstrated significantly lower muscle-related adverse events with bempedoic acid compared to statin-treated comparator arms. Option A: Option B: Option B correctly identifies ACLY inhibition and the hepatic-selective prodrug activation concept but incorrectly names the activating enzyme as "ACSL1" (long-chain acyl-CoA synthetase 1) — the correct enzyme is ACSVL1 (very-long-chain acyl-CoA synthetase 1, SLC27A2); the distinction matters pharmacologically, and this option's error makes it incorrect despite capturing the right mechanistic concept. Option C: Option D:

Option A: Option A is incorrect; bempedoic acid does not inhibit HMG-CoA reductase by any mechanism — it inhibits a different enzyme (ACLY) upstream in the same pathway; the premise of the option is pharmacologically inaccurate.
Option C: Option C is incorrect; bempedoic acid does not inhibit squalene synthase — squalene synthase inhibitors are a distinct class studied separately (e.g., lapaquistat); the mechanism described, while pharmacologically interesting, is not bempedoic acid's mechanism of action.
Option D: Option D is incorrect; bempedoic acid is not an LXR antagonist and does not work through FASN or ACSS2 inhibition — the mechanism described is pharmacologically fabricated and does not correspond to any established lipid-lowering drug.

10. A 61-year-old man with a prior MI two years ago is on rosuvastatin 40 mg plus ezetimibe 10 mg, which he takes consistently. His most recent LDL-C is 78 mg/dL — above his secondary prevention target of below 70 mg/dL. He has no diabetes, no hypertension, no recurrent events since his MI, and no other risk-enhancing features beyond the MI itself. He is otherwise tolerating his current regimen well. His cardiologist is deciding whether to add a PCSK9 inhibitor. The patient asks whether the remaining LDL-C gap of 8 mg/dL above target justifies adding an injectable, expensive medication. Which of the following best reflects current ACC/AHA guideline reasoning on PCSK9 inhibitor use in this specific clinical scenario?

A) The ACC/AHA 2018 guideline mandates PCSK9 inhibitor initiation in all secondary prevention patients with LDL-C above 70 mg/dL on maximally tolerated statin plus ezetimibe, regardless of absolute LDL-C level or absolute residual risk, because any LDL-C above the below-70 threshold constitutes an indication for the next available therapy in the stepwise framework.
B) The ACC/AHA 2018 guideline recommends against PCSK9 inhibitor use in secondary prevention patients whose LDL-C is below 100 mg/dL on statin plus ezetimibe, because the absolute cardiovascular event reduction attributable to further LDL-C lowering from 78 mg/dL to below 70 mg/dL is too small to justify the cost and complexity of adding a third agent; the guideline endorses a 70 mg/dL target for documentation purposes only.
C) PCSK9 inhibitors are not indicated in this patient because his LDL-C has already been reduced by approximately 50% or more from an estimated untreated baseline, which constitutes the guideline's definition of an adequate treatment response in secondary prevention regardless of the absolute on-treatment LDL-C value achieved.
D) The ACC/AHA 2018 guideline recommends that in very high-risk secondary prevention patients with LDL-C persistently above 70 mg/dL on maximally tolerated statin plus ezetimibe, it is reasonable to add a PCSK9 inhibitor — but also explicitly identifies cost-effectiveness as a factor in this decision and acknowledges that a patient with only modest residual elevation (LDL-C 78 mg/dL, 8 mg/dL above target) and no additional high-risk features represents a clinical judgment call rather than a clear mandate, making this a shared decision-making conversation rather than an automatic prescription.
E) Because this patient's absolute LDL-C is below 100 mg/dL, he does not qualify as a "very high-risk" secondary prevention patient under the ACC/AHA 2018 guideline definition, and PCSK9 inhibitor therapy is therefore not guideline-endorsed regardless of whether LDL-C target is met; the very high-risk designation requires LDL-C above 100 mg/dL at baseline before statin initiation.

ANSWER: D

Rationale:

The correct answer is D. The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol defines "very high-risk" secondary prevention patients as those with a history of multiple major ASCVD events or one major ASCVD event plus multiple high-risk conditions (diabetes, hypertension, CKD, current smoking, LDL-C persistently above 100 mg/dL on statin, or recurrent events). This patient — with a single prior MI and no additional high-risk features — sits in the secondary prevention category but is not unambiguously "very high-risk" by the most stringent ACC/AHA definition. For patients on maximally tolerated statin plus ezetimibe with LDL-C persistently above 70 mg/dL, the guideline states that it is reasonable to add a PCSK9 inhibitor — notably using "reasonable" rather than "recommended," signaling class IIa rather than class I evidence. Critically, the 2018 guideline explicitly incorporates cost-effectiveness into the PCSK9 inhibitor discussion, acknowledging that the absolute risk reduction from reducing LDL-C an additional 8 mg/dL (from 78 to below 70) is smaller in a patient without multiple additional high-risk features than in, for example, a patient with recurrent events and LDL-C persistently above 100 mg/dL. This is therefore explicitly a shared decision-making conversation — the physician should present the benefit-cost tradeoff honestly, and the patient's preferences regarding injection therapy and cost should inform the decision. This nuanced guideline language is clinically important: treating every LDL-C value 1 mg/dL above target as a mandatory prescription trigger is not what the guideline intends. Option A: Option B: Option C: Option E:

Option A: Option A is incorrect; the ACC/AHA guideline does not mandate PCSK9 inhibitor initiation for every secondary prevention patient above the 70 mg/dL target — it uses "reasonable" (class IIa) language and explicitly incorporates cost-effectiveness and clinical judgment, particularly for patients with modest residual LDL-C elevation and no additional high-risk features.
Option B: Option B is incorrect; the guideline does not recommend against PCSK9 inhibitors in secondary prevention patients with LDL-C below 100 mg/dL, nor does it characterize the 70 mg/dL target as a documentation-only benchmark — the target is clinically meaningful, and PCSK9 inhibitors remain guideline-reasonable when LDL-C is persistently above it on maximally tolerated therapy.
Option C: Option C is incorrect; the ACC/AHA guideline does not define treatment success solely by percentage LDL-C reduction from estimated baseline — it uses absolute on-treatment LDL-C thresholds (below 70 mg/dL for very high-risk secondary prevention) as the operative target, and percentage reduction is a secondary metric used to assess statin adherence, not the primary endpoint for escalation decisions.
Option E: Option E is incorrect; the "very high-risk" designation in the ACC/AHA 2018 guideline is based on clinical features (number of major ASCVD events, presence of high-risk conditions) — it is not defined by pre-treatment LDL-C level, and LDL-C above 100 mg/dL at baseline is one high-risk condition on the list, not a threshold criterion for the designation itself.

11. An 81-year-old woman presents for a medication review. She has hypertension, osteoarthritis, and mild cognitive impairment, but no prior cardiovascular events, no diabetes, and no established ASCVD. She is a non-smoker. Her LDL-C is 148 mg/dL. She takes amlodipine, lisinopril, and a calcium supplement. Her daughter — who accompanies her — asks whether her mother should be on a statin given her LDL-C and age. The primary care physician explains that the ACC/AHA 2018 guideline specifically addresses statin use in older adults and provides a nuanced recommendation for this age group. Which of the following most accurately reflects the ACC/AHA 2018 guideline approach to primary prevention statin therapy in adults over age 75?

A) For primary prevention in adults over age 75, the ACC/AHA 2018 guideline recommends that the decision to initiate a statin should involve a clinician-patient discussion that considers individual cardiovascular risk, comorbidity burden, life expectancy, frailty, polypharmacy risk, and patient preferences — and that if a statin is already being taken, it is reasonable to continue it; the guideline does not provide a strong class I recommendation for initiating statin therapy for primary prevention in this age group and acknowledges that evidence from randomized trials specifically in patients above age 75 is limited.
B) The ACC/AHA 2018 guideline recommends high-intensity statin therapy for all adults over age 75 with LDL-C above 130 mg/dL in the primary prevention setting, on the basis that the Pooled Cohort Equations universally assign 10-year ASCVD risk above 7.5% in adults over age 70 regardless of risk factor burden, making formal risk calculation unnecessary and statin initiation automatic at this age.
C) The ACC/AHA 2018 guideline recommends against statin initiation in all adults over age 75 for primary prevention, on the grounds that the cardiovascular benefit of LDL-C lowering in this age group is outweighed by the risks of polypharmacy, drug interactions, and statin-associated muscle symptoms in older adults with reduced renal and hepatic clearance; statins should be deprescribed rather than initiated in any patient above age 75 without established ASCVD.
D) For adults over age 75, the ACC/AHA 2018 guideline recommends initiating moderate-intensity statin therapy automatically in all patients with LDL-C above 100 mg/dL, because the guideline recognizes that patients who survive to age 75 represent a cardiovascularly resilient cohort whose remaining life expectancy is sufficient to derive full benefit from LDL-C lowering, and pharmacological therapy should not be withheld on the basis of age alone.
E) The ACC/AHA 2018 guideline recommends statin therapy exclusively for older adults who have already experienced a cardiovascular event, and withholds any primary prevention recommendation above age 75 on the grounds that the LDL hypothesis has not been validated in randomized controlled trials enrolling patients above age 80, making statin prescribing in this age group experimental rather than evidence-based.

ANSWER: A

Rationale:

The correct answer is A. The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol provides specific and nuanced guidance on statin therapy in older adults. For primary prevention in adults between ages 40 and 75, the guideline provides a tiered framework based on 10-year ASCVD risk and risk-enhancing factors. For adults above age 75 — the age group this patient belongs to — the guideline takes a more cautious and individualized approach. The guideline acknowledges that randomized controlled trial data specifically in adults above age 75 for primary prevention are limited; most major statin trials (4S, WOSCOPS, AFCAPS/TexCAPS, JUPITER) enrolled relatively few participants above age 75, and extrapolating evidence from younger populations to octogenarians requires clinical judgment. For patients already on statins, continuation is generally reasonable as they have demonstrated tolerability. For initiating a new statin for primary prevention in adults above age 75, the guideline recommends a clinician-patient risk discussion that explicitly incorporates frailty, polypharmacy, comorbidity burden, life expectancy, and patient values — recognizing that for some patients with limited life expectancy, significant comorbidity, or strong preferences against additional medications, the absolute benefit may not justify the absolute risks. This patient has mild cognitive impairment (which introduces medication adherence and drug-interaction considerations), osteoarthritis (polypharmacy context), and no established ASCVD — all of which are relevant inputs to a nuanced individualized discussion rather than automatic prescription or automatic withholding. Option B: Option C: Option D: Option E:

Option B: Option B is incorrect; the ACC/AHA guideline does not recommend automatic high-intensity statin therapy for all adults above age 75 with LDL-C above 130 mg/dL, and while the Pooled Cohort Equations do produce high 10-year risk estimates in elderly patients, the guideline does not use this as justification to bypass individualized clinical judgment in primary prevention above age 75.
Option C: Option C is incorrect; the ACC/AHA guideline does not recommend against all statin therapy in adults above age 75 — it recommends individualized decision-making and supports continuation of existing statin therapy; a blanket recommendation to deprescribe statins in all patients above age 75 without established ASCVD is not guideline-endorsed.
Option D: Option D is incorrect; the guideline does not recommend automatic moderate-intensity statin therapy for all adults above age 75 with LDL-C above 100 mg/dL — this option describes an algorithmic threshold-based approach that the guideline explicitly moves away from in this age group in favor of individualized shared decision-making.
Option E: Option E is incorrect; the guideline does not restrict statin use in older adults to secondary prevention only — it addresses primary prevention above age 75 with a nuanced recommendation for individualized discussion rather than either automatic prescribing or automatic withholding; calling primary prevention statin prescribing in this age group "experimental" misrepresents the guideline's language and intent.